The Priority Review

Tag

Rare disease

8 stories

Stories

  1. Approvals

    FDA approves pimicotinib for adults with symptomatic tenosynovial giant cell tumor

    The FDA approved pimicotinib (Pimjetmi) on November 10, 2026, after an overall response rate of 56% versus 3.2% on placebo at Week 25. For adults with symptomatic TGCT, an approved kinase inhibitor now exists.

  2. Business

    Orphalan opens China sites in Phase 3 Wilson disease trial and randomizes first participant

    Orphalan said three Chinese hospitals are now recruiting for its 38-participant TRADITiONAL Phase 3 study of once-daily trientine tetrahydrochloride. Wilson disease patients aged 8 years and older can now enroll in the United States and China.

  3. Approvals

    FDA approves Voceryq for adults with recurrent respiratory papillomatosis

    Seven of 26 adults with at least three baseline surgeries (27%) needed no surgery in the first year after Voceryq, the FDA said in granting accelerated approval. Adults with recurrent respiratory papillomatosis now have a plasmid DNA-based immunotherapy approved in the U.S.

  4. Clinical trials

    On crovalimab, 59.5 percent of treatment-naive aHUS participants had a complete TMA response

    In the Phase III COMMUTE-a study, 59.5 percent of 37 treatment-naive participants with aHUS had a complete thrombotic microangiopathy response through Week 25, the registry shows. The record covers 83 participants in three cohorts.

  5. Clinical trials

    Vertex posts Phase 3 ELX/TEZ/IVA study results in infants with cystic fibrosis

    Vertex Pharmaceuticals Incorporated posted results of a Phase 3 open-label study of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants.

  6. Clinical trials

    ACADIA posts Phase 3 carbetocin nasal spray results in Prader-Willi syndrome

    ACADIA Pharmaceuticals Inc. posted results of a 12-week Phase 3 study of carbetocin nasal spray against placebo in hyperphagia in Prader-Willi syndrome. The study enrolled 175 participants.

  7. Approvals

    FDA approves Emcitate, the first treatment for MCT8 deficiency

    Egetis Therapeutics' tiratricol treats the excess blood thyroid hormone of Allan-Herndon-Dudley syndrome. The company also received a rare pediatric disease priority review voucher.

  8. Approvals

    FDA approves Fayuvi, the first gene therapy for Sanfilippo syndrome type A

    Ultragenyx's one-time AAV9 infusion received standard full approval for children with MPS IIIA, and the company received a priority review voucher.